Published in Eur J Cancer on November 28, 1995
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg (2005) 1.06
Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer (2009) 0.93
High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg (2007) 0.92
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol (2010) 0.91
Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium. Dig Dis Sci (2002) 0.77
Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression. J Cancer Res Clin Oncol (2005) 0.75
Growth-related expression of ribosomal protein genes in Saccharomyces cerevisiae. Mol Gen Genet (1993) 14.93
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med (1994) 4.00
Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology (1996) 3.54
Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med (1989) 3.03
Transdermal nicotine for active ulcerative colitis. N Engl J Med (1994) 2.90
MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol (2001) 2.71
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology (1994) 2.22
Cosmesis and body image after laparoscopic-assisted and open ileocolic resection for Crohn's disease. Surg Endosc (1998) 1.93
Long term serological surveillance after treatment of Helicobacter pylori infection. Gut (1991) 1.90
Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut (1997) 1.88
Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet (1987) 1.83
Drug delivery to the central nervous system: a review. J Pharm Pharm Sci (2003) 1.76
Cholesterol crystal embolization in the Netherlands. Arch Intern Med (1996) 1.74
Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995. Ann Surg (1988) 1.72
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer (1996) 1.71
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood (2000) 1.69
Effect of transport medium and transportation time on culture of Helicobacter pylori from gastric biopsy specimens. J Clin Pathol (1993) 1.66
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.61
Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta (1983) 1.61
Eight novel inactivating germ line mutations at the APC gene identified by denaturing gradient gel electrophoresis. Genomics (1992) 1.59
Cholecystokinin receptors in human pancreas and gallbladder muscle: a comparative study. Gastroenterology (1996) 1.55
Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut (2003) 1.55
Satiety effects of cholecystokinin in humans. Gastroenterology (1994) 1.55
Flow cytometric detection of aneuploidy in colorectal adenomas. Cancer Res (1985) 1.53
An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach. Neth J Med (2011) 1.53
Nonulcer dyspepsia in a Dutch working population and Helicobacter pylori. Ulcer history as an explanation of an apparent association. Arch Intern Med (1995) 1.52
Effect of oral zinc supplementation on metallothionein and superoxide dismutase concentrations in patients with inflammatory bowel disease. J Gastroenterol Hepatol (1995) 1.52
A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer (1998) 1.49
Serum gastrin and mucosal somatostatin in Helicobacter pylori-associated gastritis. Scand J Gastroenterol (1995) 1.47
Upper gastrointestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheumatol (1992) 1.46
Clinical presentation of Helicobacter pylori-positive and -negative functional dyspepsia. J Gastroenterol Hepatol (2000) 1.46
Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. Am J Gastroenterol (1997) 1.46
Molecular analysis of the APC gene in 105 Dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and southern analysis. Hum Mutat (1997) 1.44
Majority of hMLH1 mutations responsible for hereditary nonpolyposis colorectal cancer cluster at the exonic region 15-16. Am J Hum Genet (1996) 1.43
Gall bladder emptying in severe idiopathic constipation. Gut (1999) 1.43
Laparoscopic-assisted vs. open ileocolic resection for Crohn's disease. A comparative study. Surg Endosc (2000) 1.38
[Combination external and internal radiotherapy for esophageal carcinoma: a new prospect]. Ned Tijdschr Geneeskd (1993) 1.38
Gallbladder motility after duodenum-preserving resection of the head of the pancreas. Scand J Gastroenterol (1997) 1.38
Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Aliment Pharmacol Ther (1987) 1.38
The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC). Int J Cancer (1996) 1.35
Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav (2012) 1.35
Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol (2001) 1.33
Cloning and functional characterization of DSCAML1, a novel DSCAM-like cell adhesion molecule that mediates homophilic intercellular adhesion. Biochem Biophys Res Commun (2001) 1.31
High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav (2012) 1.30
Pneumatosis cystoides intestinalis in intestinal pseudoobstruction. Resolution after therapy with metronidazole. Dig Dis Sci (1992) 1.29
Cholecystokinin-octapeptidelike immunoreactivity in human plasma. Gastroenterology (1982) 1.29
Proximal Crohn's disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis (2001) 1.26
The value of screening and central registration of families with familial adenomatous polyposis. A study of 82 families in The Netherlands. Dis Colon Rectum (1990) 1.25
The tumour spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in the Netherlands. Int J Cancer (1990) 1.24
Close linkage of a highly polymorphic marker (D5S37) to familial adenomatous polyposis (FAP) and confirmation of FAP localization on chromosome 5q21-q22. Hum Genet (1988) 1.20
Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology (1990) 1.19
The effect of loxiglumide (CR-1505) on basal and bombesin-stimulated gallbladder volume in man. Eur J Pharmacol (1989) 1.19
Urokinase receptor and colorectal cancer survival. Lancet (1994) 1.18
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res (1994) 1.18
Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut (1999) 1.18
Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut (1989) 1.17
Transcription activation of yeast ribosomal protein genes requires additional elements apart from binding sites for Abf1p or Rap1p. Nucleic Acids Res (1995) 1.17
Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer (2006) 1.16
Influence of age and Helicobacter pylori infection on serum pepsinogens in healthy blood transfusion donors. Gut (1992) 1.16
Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab (1989) 1.15
Crohn's disease of the upper gastrointestinal tract. Neth J Med (1997) 1.14
Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer. Clin Cancer Res (2000) 1.14
Serum concentrations of immunoreactive calcitonin in patients with hypergastrinaemia. Digestion (1980) 1.13
Effect of graded physiologic doses of cholecystokinin on gallbladder contraction measured by ultrasonography. Determination of threshold, dose-response relationships and comparison with intraduodenal bilirubin output. Gastroenterology (1985) 1.13
Prospective comparative study of the influence of postoperative bile reflux on gastric mucosal histology and Campylobacter pylori infection. Gut (1989) 1.11
Pancreatic enzyme response to a liquid meal and to hormonal stimulation. Correlation with plasma secretin and cholecystokinin levels. J Clin Invest (1985) 1.11
The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment. Scand J Gastroenterol Suppl (1997) 1.11
Superoxide dismutases in relation to the overall survival of colorectal cancer patients. Br J Cancer (1998) 1.10
A computerized method for rapid quantification of gallbladder volume from real-time sonograms. Radiology (1985) 1.10
Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain (2001) 1.10
Advances in the genetics of progressive myoclonus epilepsy. Am J Med Genet (2001) 1.09
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res (1987) 1.09
Motor and sensory function of the proximal stomach in reflux disease and after laparoscopic Nissen fundoplication. Am J Gastroenterol (1999) 1.09
Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. Gut (1994) 1.09
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology (1991) 1.08
Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology (1984) 1.08
Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer (1987) 1.08
Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res (2000) 1.07
Glucose-triggered signalling in Saccharomyces cerevisiae: different requirements for sugar phosphorylation between cells grown on glucose and those grown on non-fermentable carbon sources. Microbiology (1996) 1.06
Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood (2001) 1.06